File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Problems in the use of urinary hCG-beta-core as a tumor marker in gynecologic cancer

TitleProblems in the use of urinary hCG-beta-core as a tumor marker in gynecologic cancer
Authors
Keywordsgynecologic cancer
spot and early morning urine
urinary hCG-beta-core
Issue Date1995
PublisherLippincott Williams & Wilkins. The Journal's web site is located at http://www.ijgc.net/
Citation
International Journal Of Gynecological Cancer, 1995, v. 5 n. 1, p. 15-19 How to Cite?
AbstractUrinary human chorionic gonadotrophin beta-core (hCG-βC) was detected in 55-77% of gynecologic malignancies. The use of spot and early morning urine hCG-βC as a tumor marker was explored with regard to the stability of the hCG-βC level in serial spot urine samples collected within 24 hours and in early morning urine collected over 3 days. Thirteen patients with gynecologic malignancies were asked, before treatment, to collect serial urine samples voided within 24 hours. Nine of these 13 patients were also asked to save early morning urine for 2-3 consecutive days. Their urine was assayed for creatinine and hCG-βC using an immunoradiometric assay. Variation of urine concentration was corrected by using the hCG-βC/creatinine (βC/Cr) ratio expressed in pmolg-1. Wide fluctuations of βC/Cr ratios were found both in the serial spot urine within 24 hours and in early morning urine within 3 days. Eight per cent of the patients had one or more spot hCG-βC level double or half the median of their own serial urine samples. Neither spot urine nor early morning urine hCG-βC were suitable for use as a tumor marker for continuous monitoring because of the large fluctuation in hCG-βC levels. The reason for such a wide fluctuation is not clear.
Persistent Identifierhttp://hdl.handle.net/10722/87086
ISSN
2015 Impact Factor: 2.116
2015 SCImago Journal Rankings: 0.830
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorNgan, HYSen_HK
dc.contributor.authorYeung, WSBen_HK
dc.contributor.authorCheng, GTSen_HK
dc.contributor.authorWong, LCen_HK
dc.contributor.authorDe Madeiros, SFen_HK
dc.contributor.authorNorman, RJen_HK
dc.contributor.authorMa, HKen_HK
dc.date.accessioned2010-09-06T09:25:08Z-
dc.date.available2010-09-06T09:25:08Z-
dc.date.issued1995en_HK
dc.identifier.citationInternational Journal Of Gynecological Cancer, 1995, v. 5 n. 1, p. 15-19en_HK
dc.identifier.issn1048-891Xen_HK
dc.identifier.urihttp://hdl.handle.net/10722/87086-
dc.description.abstractUrinary human chorionic gonadotrophin beta-core (hCG-βC) was detected in 55-77% of gynecologic malignancies. The use of spot and early morning urine hCG-βC as a tumor marker was explored with regard to the stability of the hCG-βC level in serial spot urine samples collected within 24 hours and in early morning urine collected over 3 days. Thirteen patients with gynecologic malignancies were asked, before treatment, to collect serial urine samples voided within 24 hours. Nine of these 13 patients were also asked to save early morning urine for 2-3 consecutive days. Their urine was assayed for creatinine and hCG-βC using an immunoradiometric assay. Variation of urine concentration was corrected by using the hCG-βC/creatinine (βC/Cr) ratio expressed in pmolg-1. Wide fluctuations of βC/Cr ratios were found both in the serial spot urine within 24 hours and in early morning urine within 3 days. Eight per cent of the patients had one or more spot hCG-βC level double or half the median of their own serial urine samples. Neither spot urine nor early morning urine hCG-βC were suitable for use as a tumor marker for continuous monitoring because of the large fluctuation in hCG-βC levels. The reason for such a wide fluctuation is not clear.en_HK
dc.languageengen_HK
dc.publisherLippincott Williams & Wilkins. The Journal's web site is located at http://www.ijgc.net/en_HK
dc.relation.ispartofInternational Journal of Gynecological Canceren_HK
dc.subjectgynecologic canceren_HK
dc.subjectspot and early morning urineen_HK
dc.subjecturinary hCG-beta-coreen_HK
dc.titleProblems in the use of urinary hCG-beta-core as a tumor marker in gynecologic canceren_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=1048-891X&volume=5&spage=15&epage=19&date=1995&atitle=Problems+in+the+use+of+urinary+hCG-beta-core+as+a+tumor+marker+in+gynaecologic+canceren_HK
dc.identifier.emailNgan, HYS:hysngan@hkucc.hku.hken_HK
dc.identifier.emailYeung, WSB:wsbyeung@hkucc.hku.hken_HK
dc.identifier.authorityNgan, HYS=rp00346en_HK
dc.identifier.authorityYeung, WSB=rp00331en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1046/j.1525-1438.1995.05010015.xen_HK
dc.identifier.scopuseid_2-s2.0-0028924549en_HK
dc.identifier.hkuros3136en_HK
dc.identifier.volume5en_HK
dc.identifier.issue1en_HK
dc.identifier.spage15en_HK
dc.identifier.epage19en_HK
dc.identifier.isiWOS:A1995QA17800003-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridNgan, HYS=34571944100en_HK
dc.identifier.scopusauthoridYeung, WSB=7102370745en_HK
dc.identifier.scopusauthoridCheng, GTS=8049877500en_HK
dc.identifier.scopusauthoridWong, LC=7402092003en_HK
dc.identifier.scopusauthoridDe Madeiros, SF=6504167636en_HK
dc.identifier.scopusauthoridNorman, RJ=7202169731en_HK
dc.identifier.scopusauthoridMa, HK=7403095603en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats